铁缺乏
绝对性铁缺乏由生理需求增加、摄入减少、吸收障碍或慢性失血引起。组织水平由铁调节蛋白调控,全身水平通过抑制铁调素增加铁释放。诊断需排除炎症掩盖,所有病例应评估治疗与病因,疟疾流行区需警惕铁治疗加重感染。口服铁基于铁调素生理优化方案,静脉铁(尤其新一代高剂量单次输注)因起效快、持久且安全性可接受而成为更多情况下的有效选择,需个体化权衡风险获益。
要点
- 绝对性铁缺乏原因包括生理需求增加、摄入减少、吸收障碍或慢性失血。
- 所有铁缺乏病例应评估治疗与病因,疟疾流行区需警惕铁治疗加重感染。
核心结论
- 所有铁缺乏病例应评估治疗与病因,疟疾流行区需警惕铁治疗加重感染。
- 静脉铁尤其新一代高剂量单次输注因起效快、持久且安全性可接受,正成为更多情况下的有效替代。
- 不同治疗的风险获益需在个体化治疗中权衡。
主要发现
- 绝对性铁缺乏由儿童、青少年、年轻及妊娠女性的生理性铁需求增加、铁摄入减少、病理性吸收缺陷或慢性失血引起。
- 组织水平适应由铁调节蛋白控制以增加铁摄取和保留;全身水平通过抑制铁调素增加吸收性肠上皮细胞和回收巨噬细胞向血浆释放铁。
- 除非被炎症状态掩盖,绝对性铁缺乏诊断容易。
- 静脉铁尤其新一代高剂量单次输注因血液学反应更快速持久且安全性可接受,正成为更多情况下的有效替代。
临床怎么用
- 所有铁缺乏病例应评估治疗与病因。
- 疟疾和其他感染流行区需特别注意避免铁治疗加重感染。
- 基于铁调素控制生理的口服铁给药方案旨在优化铁盐治疗并减少常见不良反应。
- 不同治疗的风险获益应在个体化治疗中权衡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency anemia affects >1.2 billions individuals worldwide, and iron deficiency in the absence of anemia is even more frequent. Total-body (absolute) iron deficiency is caused by physiologically increased iron requirements in children, adolescents, young and pregnant women, by reduced iron intake, or by pathological defective absorption or chronic blood loss. Adaptation to iron deficiency at the tissue level is controlled by iron regulatory proteins to increase iron uptake and retention; at the systemic level, suppression of the iron hormone hepcidin increases iron release to plasma by absorptive enterocytes and recycling macrophages. The diagnosis of absolute iron deficiency is easy unless the condition is masked by inflammatory conditions. All cases of iron deficiency should be assessed for treatment and underlying cause. Special attention is needed in areas endemic for malaria and other infections to avoid worsening of infection by iron treatment. Ongoing efforts aim at optimizing iron salts-based therapy by protocols of administration based on the physiology of hepcidin control and reducing the common adverse effects of oral iron. IV iron, especially last-generation compounds administered at high doses in single infusions, is becoming an effective alternative in an increasing number of conditions because of a more rapid and persistent hematological response and acceptable safety profile. Risks/benefits of the different treatments should be weighed in a personalized therapeutic approach to iron deficiency.
引用
- Camaschella C. Iron deficiency. Blood. 2018. PMID: 30401704. doi:10.1182/blood-2018-05-815944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。